Create Account | Sign In: Author or Forum

 
 
News  |  Journals  |  Conferences  |  Blogs  |  Articles  |  Forums  |  Twitter    
 

 Headlines:

 

Category: Cardiology | Family Medicine | Internal Medicine | Journal

Back to Journal Articles

Everolimus-Eluting Stents Found Safe and Effective

Last Updated: June 18, 2009.

 

Six-month outcomes may be superior to bare-metal and paclitaxel-eluting stents

Share |

Comments: (0)

Tell-a-Friend

 

  Related
 
In unselected patients with coronary artery disease -- including those considered high risk -- everolimus-eluting stents may be as safe as bare-metal stents, sirolimus-eluting stents and paclitaxel-eluting stents, and more effective than either bare-metal or paclitaxel-eluting stents, according to a study published early online June 17 in the Journal of the American College of Cardiology.

THURSDAY, June 18 (HealthDay News) -- In unselected patients with coronary artery disease -- including those considered high risk -- everolimus-eluting stents may be as safe as bare-metal stents, sirolimus-eluting stents and paclitaxel-eluting stents, and more effective than either bare-metal or paclitaxel-eluting stents, according to a study published early online June 17 in the Journal of the American College of Cardiology.

Yoshinobu Onuma, M.D., from the Erasmus Medical Center in Rotterdam, Netherlands, and colleagues compared six-month outcomes in 649 patients who received everolimus-eluting stents, 450 who received bare-metal stents, 508 who received sirolimus-eluting stents, and 576 who received paclitaxel-eluting stents.

Compared to everolimus-eluting stents, the researchers found that bare-metal stents were associated with a higher risk of target vessel revascularization and major adverse cardiac events (adjusted hazard ratios, 2.02 and 2.15, respectively) and that paclitaxel-eluting stents were associated with an increased risk of major adverse cardiac events (adjusted hazard ratio, 1.57). They also found that clinical outcomes were similar in patients who received everolimus-eluting or sirolimus-eluting stents.

"In the present study, the rate of overall stent thrombosis at six months was similar in the everolimus-eluting stents and other stent groups, although there were no incidences of late stent thromboses with everolimus-eluting stents up to six months," the authors write. "Larger studies with longer follow-up will be necessary to assess the differential effects of everolimus-eluting stents on late and very late stent thrombosis."

Abstract
Full Text

Copyright © 2009 ScoutNews, LLC. All rights reserved.


Previous: Statin Cuts Post-Heart Attack Heart Failure Risk Next: AMA: Policy Statement Supports Health Care Reform

Reader comments on this article are listed below. Review our comments policy.


Submit your opinion:

Name:

Email:

Location:

URL:

Remember my personal information

Notify me of follow-up comments?

advertisement.gif (61x7 -- 0 bytes)
 

Are you a Doctor, Pharmacist, PA or a Nurse?

Join the Doctors Lounge online medical community

  • Editorial activities: Publish, peer review, edit online articles.

  • Ask a Doctor Teams: Respond to patient questions and discuss challenging presentations with other members.

Doctors Lounge Membership Application

 
     

 advertisement.gif (61x7 -- 0 bytes)

 

 

Useful Sites
MediLexicon
  Tools & Services: Follow DoctorsLounge on Twitter Follow us on Twitter | RSS News | Newsletter | Contact us
Copyright © 2001-2014
Doctors Lounge.
All rights reserved.

Medical Reference:
Diseases | Symptoms
Drugs | Labs | Procedures
Software | Tutorials

Advertising
Links | Humor
Forum Archive
CME | Conferences

Privacy Statement
Terms & Conditions
Editorial Board
About us | Email

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.